3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Multiple Myeloma
10
Leukemia, Myeloid, Acute
4
Lymphoma, Large B-Cell, Diffuse
3
Recurrence
2
Waldenstrom Macroglobulinemia
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Biphenotypic, Acute
1
Gliosarcoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Dendritic Cell Sarcoma, Interdigitating
1
Interventions
Cyclophosphamide
7
fludarabine
6
Whole-Body Irradiation
6
Tacrolimus
6
Mycophenolic Acid
6
ruxolitinib
5
fludarabine phosphate
5
Melphalan
5
venetoclax
4
Peripheral Blood Stem Cell Transplantation
4
itacitinib
3
Specimen Handling
3
Sirolimus
3
Granulocyte Colony-Stimulating Factor
3
Cytarabine
3
Biopsy
3
Azacitidine
3
navitoclax
2
luspatercept
2
Etoposide
2
Daunorubicin
2
Busulfan
2
Antilymphocyte Serum
2
thymoglobulin
1
selinexor
1
quizartinib
1
pomalidomide
1
plerixafor
1
pevonedistat
1
parsaclisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Myeloproliferative Disorders
×
selinexor
×
Clear all
NCT04562389
2026-04-09
SENTRY
Karyopharm Therapeutics Inc
Phase 3
Active not recruiting
353 enrolled